← Back to Clinical Trials
Recruiting NCT05814146

NCT05814146 Trial of Variable Dialysate Bicarbonate

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05814146
Status Recruiting
Phase
Sponsor Brigham and Women's Hospital
Condition Peri-dialytic Cardiac Rhythms
Study Type INTERVENTIONAL
Enrollment 141 participants
Start Date 2023-08-24
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 120 Years
Study Type INTERVENTIONAL
Interventions
Dialysate bicarbonate concentrationDialysate bicarbonate concentration - telemetry monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 141 participants in total. It began in 2023-08-24 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

QTc prolongation and premature ventricular contractions (PVCs) are common in hemodialysis (HD) patients and are associated with sudden cardiac death. It is known that higher dialysate bicarbonate is associated with more QTc prolongation during HD sessions. This study aims to assess the effects of lower (30 mEq/L) versus higher (35 mEq/L) dialysate bicarbonate in adult maintenance HD patients admitted to the hospital. The investigators will randomly assign subjects to lower versus higher dialysate bicarbonate concentrations during their hospital stay for up to a maximum of six HD sessions or until their hospital discharge.

Eligibility Criteria

Inclusion Criteria: * prevalent end-stage renal disease, on maintenance HD \> 90 days * age ≥ 18 years old * thrice weekly HD Exclusion Criteria: * hemoglobin \< 8.0 g/dL * pregnancy * any physical, mental or medical condition which limited the ability to provide written informed consent

Contact & Investigator

Central Contact

Katherine S Ravi, MD, MPH

✉ ksravi@bwh.harvard.edu

📞 (617) 732-6383

Principal Investigator

Katherine S Ravi, MD, MPH

PRINCIPAL INVESTIGATOR

Brigham and Women's Hospital

Frequently Asked Questions

Who can join the NCT05814146 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Peri-dialytic Cardiac Rhythms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05814146 currently recruiting?

Yes, NCT05814146 is actively recruiting participants. Contact the research team at ksravi@bwh.harvard.edu for enrollment information.

Where is the NCT05814146 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT05814146 clinical trial?

NCT05814146 is sponsored by Brigham and Women's Hospital. The principal investigator is Katherine S Ravi, MD, MPH at Brigham and Women's Hospital. The trial plans to enroll 141 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology